UNITED STATES SECURITIES AND EXCHANGE COMMISSION For the quarterly period ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to WASHINGTON, D.C. 20549 Commission file number 0-51813 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 LIQUIDITY SERVICES, INC. (Exact Name of Registrant as Specified in Its Charter) (State or Other Jurisdiction of (I.R.S. E ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________ FORM 10-Q __________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________to ________ Commission File Number: 001-373 ...

Financial Performance - Net sales for the three months ended December 31, 2025, were $4,229 million, a 5.6% increase from $4,004 million in the same period of 2024[186]. - For the six months ended December 31, 2025, net sales reached $7,710 million, reflecting a 5% increase from $7,365 million in the previous year[210]. - Net sales for the three months ended December 31, 2025, were reported at $4,229 million, a 6% increase from $4,004 million in the prior year[210]. - Total revenue for the six months ended December 31, 2025, was $7,710 million, an increase of 5% compared to $7,365 million in the same period of 2024[291]. - The Americas region generated net sales of $1,218 million in Q2 2025, slightly up from $1,209 million in Q2 2024[188]. - Reported net sales in The Americas decreased 1% for the six months ended December 31, 2025, driven by a 2% decrease from pricing[245]. Profitability - Gross profit margin improved to 76.5% in Q2 2025 from 76.1% in Q2 2024, with gross profit reaching $3,235 million[186]. - Operating income for the three months ended December 31, 2025, was $401 million, compared to an operating loss of $580 million in the same period of 2024[186]. - Reported operating income for the three months ended December 31, 2025, was $401 million, a $981 million increase from the prior-year period[255]. - Operating income for the six months ended December 31, 2025, was $570 million, a significant increase of $1,271 million from a loss of $701 million in the prior year[287]. - The effective tax rate increased to 51.40% for the three months ended December 31, 2025, from 9.20% in the prior year, primarily due to losses before income taxes and the impact of goodwill impairment[277]. Product Category Performance - Skin Care product category net sales increased to $2,054 million in Q2 2025, up from $1,921 million in Q2 2024, representing a 6.9% growth[188]. - Skin care net sales increased by $133 million, or 7%, for the three months ended December 31, 2025, and by $179 million, or 5%, for the six months ended December 31, 2025[217]. - Fragrance net sales rose by $68 million, or 9%, for the three months ended December 31, 2025, and by $159 million, or 12%, for the six months ended December 31, 2025[231]. - Reported makeup net sales increased slightly by $14 million, or 1%, for the three months ended December 31, 2025[224]. - Reported hair care net sales increased $9 million, or 6%, for the three months ended December 31, 2025, primarily due to higher sales from The Ordinary and the launch in Amazon's U.S. Premium Beauty store[235]. Challenges and Risks - The company anticipates continued volatility and uncertainty in its business environment, particularly in Western Europe and the U.S. department store sector[194]. - The company continues to face challenges from inflationary pressures and supply chain issues, which may impact consumer preferences and overall profitability[198]. - The company expects to continue facing challenges related to foreign currency translation and restructuring charges in future periods[281]. - The company is monitoring the effects of tariffs and expects higher rates to adversely affect fiscal 2026 profitability and cash flows[195]. Strategic Initiatives - The strategic vision "Beauty Reimagined" aims to enhance consumer engagement and drive sustainable growth through operational efficiencies[197]. - The introduction of new products is expected to impact sales, with ongoing innovation and marketing efforts to support both new and existing products[191]. - The restructuring program is expected to result in charges totaling between $1,200 million and $1,600 million, before taxes[207]. - The restructuring program aims to achieve annual gross benefits of between $800 million and $1,000 million, before taxes, once fully implemented[208]. Cash Flow and Debt Management - The company had cash and cash equivalents of $3,082 million as of December 31, 2025, compared to $2,921 million at June 30, 2025[297]. - Net cash flows provided by operating activities for the six months ended December 31, 2025, were $785 million, compared to $387 million in the same period of 2024[308]. - Total debt as of December 31, 2025, was $7,322 million, with long-term debt comprising $7,319 million and current debt of $3 million[304]. - Total debt as a percentage of total capitalization was 64.5% at December 31, 2025, down from 65.4% at June 30, 2025[307]. Market Performance - The increase in net sales from La Mer and Estée Lauder was primarily driven by higher sales in Mainland China and Asia travel retail, reflecting key shopping moments and holiday campaigns[218][219]. - Reported net sales in Mainland China increased 13% for the three months ended December 31, 2025, driven by a 9% increase from pricing and a 4% increase from volume[244]. - Operating income in Mainland China increased by $73 million, or 97%, for the three months ended December 31, 2025, and $101 million, or over 100%, for the six months ended December 31, 2025, driven by higher net sales[272].

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2025, or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 0-16125 FASTENAL COMPANY (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorp ...

Washington, D.C. 20549 _________________________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 10-Q _________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended December 31, 2025 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from _______ to _______ Commission file number 1-12383 _______________________ ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2026 Commission file number: 1-10110 BANCO BILBAO VIZCAYA ARGENTARIA, S.A. (Exact name of Registrant as specified in its charter) BANK BILBAO VIZCAYA ARGENTARIA, S.A. (Translation of Registrant's name into English) Calle Azul, 4 28050 Madrid Spain (Address of principal executive offices) Indica ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: December 28, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-37502 MASTERCRAFT BOAT HOLDINGS, INC. (Exact name of registrant as specified in its charter) (State or Other Jurisdiction (I.R.S. Emplo ...

Financial Performance - Revenues decreased by $0.7 million, or 0.3%, to $261.2 million for the three months ended December 31, 2025, compared to $261.9 million for the same period in 2024[115] - Gross profit increased by $4.6 million to $161.7 million, with a gross profit margin of 61.9%, up from 60.0% in the prior year[117] - Operating income surged by $54.6 million to $83.3 million, compared to $28.7 million in the previous year[117] - Net income reached $44.1 million, a significant increase from $0.0 million in the prior year[117] - Cost of products sold decreased by $5.3 million, or 5.1%, to $99.5 million, representing 38.1% of revenues, down from 40.0%[118] - Selling and administrative expenses fell by $3.5 million, or 4.3%, to $77.6 million, primarily due to lower compensation expenses[119] - Research and development expenses dropped by $15.7 million, or 77.3%, to $4.6 million, reflecting the discontinuation of the insulin patch pump program[120] Debt and Liquidity - As of December 31, 2025, Embecta's total principal debt issued amounted to $1,379.3 million, with long-term debt at $1,352.9 million after accounting for current debt obligations and issuance costs[128][130] - Embecta's total debt as of December 31, 2025, was $1,362.4 million, with short-term debt constituting 0.7% of total debt and a weighted average cost of total debt at 6.1%[128] - The company made interest payments of $13.2 million on outstanding debt during the three months ended December 31, 2025, and paid approximately $37.5 million on the Term Loan, of which $35.1 million was discretionary[130] - Cash and equivalents, along with restricted cash, decreased to $204.4 million as of December 31, 2025, down from $228.6 million as of September 30, 2025, primarily due to financing activities[138] - The company maintains sufficient liquidity through cash, cash equivalents, and borrowing capacity to meet operational and growth needs[127] - The effective tax rate decreased to 25.1% from 100.0% in the prior year, due to changes in earnings mix and lower limitations on interest expense deductibility[126] Operational Risks and Challenges - Future cash flows and financial performance are subject to various risks, including competitive factors and the ability to replace services currently provided by BD[147] - Operating costs have increased due to new tariffs imposed by the U.S. and foreign governments, affecting raw materials and energy costs[149] - The company faces risks from the global trade environment, with potential shifts in customer preferences towards local products due to tariffs[149] - Changes in reimbursement practices and foreign currency exchange rates could adversely impact financial performance[149][150] - Interest rate risk is primarily related to the Term Loan, with a potential $6.8 million impact on interest expense from a 100 basis point change in rates[153] - The impact of geopolitical instability and pandemics on operations and supply chains remains a concern for the company[149] Strategic Initiatives - The company is focused on the expected benefits of its Separation from BD and the associated risks of dis-synergy costs[149] - There are risks related to the completion of strategic partnerships and acquisitions that could accelerate growth and access to new technologies[149] - The company is undergoing a Patch Pump Program Restructuring Plan and a 2025 Restructuring Plan, with expectations on costs and profitability[149] - The ability to obtain FDA clearance for new products is critical for the company's future business decisions and market success[149] - The company has entered into foreign currency forward exchange contracts to manage currency exposure, which helps offset gains and losses[151][152] Credit Ratings and Compliance - Embecta's credit ratings were reaffirmed by Moody's at B1 and by Standard & Poor's at B+ in early 2026[136] - The company is in compliance with all financial covenants related to its credit agreements as of December 31, 2025[128]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the prece ...

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 28, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to______ Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | Commission File No. | Name of Registrant, State of Incorporation, Address of Principal Offices, and Telephone No. | IRS Employer I ...